SRR934730
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.669
- G2M_CHECKPOINT+0.636
- MYC_TARGETS_V1+0.577
- INTERFERON_ALPHA_RESPONSE+0.559
- MTORC1_SIGNALING+0.532
- INTERFERON_GAMMA_RESPONSE+0.521
- PROTEIN_SECRETION+0.516
- MYC_TARGETS_V2+0.477
- MITOTIC_SPINDLE+0.471
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.468
Top 10 suppressed
- KRAS_SIGNALING_DN-0.476
- PANCREAS_BETA_CELLS-0.285
- SPERMATOGENESIS-0.211
- MYOGENESIS-0.197
- XENOBIOTIC_METABOLISM-0.043
- BILE_ACID_METABOLISM-0.041
- ESTROGEN_RESPONSE_EARLY-0.015
- HEDGEHOG_SIGNALING+0.016
- WNT_BETA_CATENIN_SIGNALING+0.052
- ESTROGEN_RESPONSE_LATE+0.069
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.972 |
| 2 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.972 |
| 3 | 1A9B5D3A-CEB0-4225-9C3D-CBE98A007A3A | — | — | 0.970 |
| 4 | SRR934965 | — | — | 0.968 |
| 5 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.966 |
| 6 | SRR934837 | — | — | 0.965 |
| 7 | SRR934867 | — | — | 0.965 |
| 8 | 228C2042-804C-47FA-B565-1993E1015D40 | — | — | 0.964 |
| 9 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.963 |
| 10 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.963 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.669 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.636 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.577 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.559 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.532 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.521 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.516 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.477 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.471 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.468 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.466 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.465 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.458 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.445 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.444 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.438 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.415 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.415 | Idelalisib | — uncovered |
| APOPTOSIS | 0.409 | Idelalisib | — uncovered |